Q2/2024 6/30/2024 EPS -0.070 ZacksConsensus -0.120 ActVsEst 0.050 - Beat
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024GlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
CRVS
Earnings
- 5/6/24 - In-Line
CRVS
Sec Filings
- 10/23/24 - Form 8-K
- 8/16/24 - Form EFFECT
- CRVS's page on the SEC website